Clinical TrialJun 14, 2026, 10:01 AM
Mineralys Lorundrostat Reduces Heart Failure Risk Biomarkers
AI Summary
Mineralys Therapeutics presented new data from a post hoc analysis of its Launch-HTN and Advance-HTN trials, showing that lorundrostat was associated with significant reductions in heart failure risk biomarkers. The analysis, presented at ENDO 2026, indicated coordinated reductions in biomarkers of fibrosis and heart failure, suggesting lorundrostat may favorably modulate physiological processes driving heart failure. These findings provide biological plausibility and support further evaluation of lorundrostat's therapeutic potential in this setting. Lorundrostat is currently under review by the U.S. FDA, with a PDUFA target date of December 22, 2026.
Key Highlights
- Lorundrostat significantly reduced heart failure risk biomarkers in a proteomic analysis.
- Analysis included data from 1,004 participants in Phase 3 Launch-HTN and Phase 2b Advance-HTN trials.
- Lorundrostat led to coordinated reductions in biomarkers of fibrosis and heart failure.
- Significant reductions were observed in 6 of 11 candidate causal risk biomarkers of incident HF, including NT-proBNP.
- The data supports further evaluation of lorundrostat's therapeutic potential in heart failure.
- Lorundrostat is currently under FDA review with a PDUFA target date of December 22, 2026.
Price Impact
More from MLYS